Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

GAS6 receptor status is associated with dormancy and bone metastatic tumor formation.

Taichman RS, Patel LR, Bedenis R, Wang J, Weidner S, Schumann T, Yumoto K, Berry JE, Shiozawa Y, Pienta KJ.

PLoS One. 2013 Apr 24;8(4):e61873. doi: 10.1371/journal.pone.0061873. Print 2013.

2.

Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow.

Jung Y, Decker AM, Wang J, Lee E, Kana LA, Yumoto K, Cackowski FC, Rhee J, Carmeliet P, Buttitta L, Morgan TM, Taichman RS.

Oncotarget. 2016 May 3;7(18):25698-711. doi: 10.18632/oncotarget.8365.

3.

Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow.

Yumoto K, Eber MR, Wang J, Cackowski FC, Decker AM, Lee E, Nobre AR, Aguirre-Ghiso JA, Jung Y, Taichman RS.

Sci Rep. 2016 Nov 7;6:36520. doi: 10.1038/srep36520.

4.

Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.

Mishra A, Wang J, Shiozawa Y, McGee S, Kim J, Jung Y, Joseph J, Berry JE, Havens A, Pienta KJ, Taichman RS.

Mol Cancer Res. 2012 Jun;10(6):703-12. doi: 10.1158/1541-7786.MCR-11-0569. Epub 2012 Apr 19.

5.

Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.

Cackowski FC, Eber MR, Rhee J, Decker AM, Yumoto K, Berry JE, Lee E, Shiozawa Y, Jung Y, Aguirre-Ghiso JA, Taichman RS.

J Cell Biochem. 2017 Apr;118(4):891-902. doi: 10.1002/jcb.25768. Epub 2016 Nov 10.

6.

GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche.

Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ, Taichman RS.

Neoplasia. 2010 Feb;12(2):116-27.

7.

Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.

Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, Patel L, Carmeliet P, Daignault S, Keller ET, McCauley LK, Pienta KJ, Taichman RS.

Neoplasia. 2012 May;14(5):429-39.

8.

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Dantas-Barbosa C, Lesluyes T, Loarer FL, Chibon F, Treilleux I, Coindre JM, Meeus P, Brahmi M, Bally O, Ray-Coquard I, Sunyach MP, Cesne AL, Mir O, Bonvalot S, Toulmonde M, Italiano A, Saintigny P, Jean-Denis M, Ducimetiere F, Ranchere D, El Sayadi H, Alberti L, Blay JY.

Br J Cancer. 2017 Dec 5;117(12):1787-1797. doi: 10.1038/bjc.2017.354. Epub 2017 Oct 12.

9.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.

Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S.

Leukemia. 2015 Mar;29(3):696-704. doi: 10.1038/leu.2014.236. Epub 2014 Aug 8.

PMID:
25102945
10.

Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.

Brown JE, Krodel M, Pazos M, Lai C, Prieto AL.

PLoS One. 2012;7(5):e36800. doi: 10.1371/journal.pone.0036800. Epub 2012 May 14.

11.

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.

Schmitz R, Valls AF, Yerbes R, von Richter S, Kahlert C, Loges S, Weitz J, Schneider M, Ruiz de Almodovar C, Ulrich A, Schmidt T.

Oncotarget. 2016 Aug 30;7(35):56355-56370. doi: 10.18632/oncotarget.10889.

12.

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.

Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM.

Cancer Res. 2011 Mar 1;71(5):1792-804. doi: 10.1158/0008-5472.CAN-10-2186. Epub 2011 Feb 22.

13.

Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.

Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC.

J Cell Physiol. 2005 Jul;204(1):36-44.

PMID:
15605394
14.

Up-regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates with Gas6 in established multiple sclerosis lesions.

Weinger JG, Omari KM, Marsden K, Raine CS, Shafit-Zagardo B.

Am J Pathol. 2009 Jul;175(1):283-93. doi: 10.2353/ajpath.2009.080807. Epub 2009 Jun 18.

15.

Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow.

Decker AM, Jung Y, Cackowski FC, Yumoto K, Wang J, Taichman RS.

Mol Cancer Res. 2017 Dec;15(12):1644-1655. doi: 10.1158/1541-7786.MCR-17-0132. Epub 2017 Aug 16.

PMID:
28814453
16.

Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.

Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S, Hanemann CO.

Oncogene. 2014 Jan 16;33(3):336-46. doi: 10.1038/onc.2012.587. Epub 2013 Jan 14.

PMID:
23318455
17.

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.

Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Jones DS 2nd, Kapur S, Mathews II, Koong AC, Rankin EB, Cochran JR, Giaccia AJ.

J Clin Invest. 2017 Jan 3;127(1):183-198. doi: 10.1172/JCI85610. Epub 2016 Nov 28.

18.

Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.

Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G.

Elife. 2014 Sep 29;3. doi: 10.7554/eLife.03385.

19.

Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas.

el Sayadi H, Pissaloux D, Alberti L, Tabone-Eglinger S, Ranchere D, Decouvelaere AV, Tabone E, Ray-Coquard I, Caux C, Fayette J, Blay JY.

Target Oncol. 2013 Dec;8(4):261-9. doi: 10.1007/s11523-012-0249-2. Epub 2013 Jan 25.

PMID:
23354874
20.

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.

Kariolis MS, Miao YR, Jones DS 2nd, Kapur S, Mathews II, Giaccia AJ, Cochran JR.

Nat Chem Biol. 2014 Nov;10(11):977-83. doi: 10.1038/nchembio.1636. Epub 2014 Sep 21.

Supplemental Content

Support Center